Jin Lu, Zhang Zeng, Li Yifan, He Tao, Hu Jia, Liu Jiaju, Chen Mingwei, Gui Yaoting, Chen Yun, Lai Yongqing
Department of Urology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, P.R. China.
Department of Urology, Anhui Medical University, Hefei, Anhui 230032, P.R. China.
Oncol Lett. 2017 Jun;13(6):4512-4520. doi: 10.3892/ol.2017.5985. Epub 2017 Apr 4.
MicroRNA (miR)-125b has been identified as deregulated in a number of types of cancer. Previous studies have detected the expression of miR-125b in clear cell renal cell carcinoma (ccRCC) tissues by hybridization and revealed that miR-125b was upregulated in ccRCC tissues, and was associated with recurrence and survival of patients with ccRCC. However, the function of miR-125b in RCC remains unclear. Thus, the expression of miR-125b was detected with quantitative polymerase chain reaction (qPCR) in 24 paired RCC and adjacent normal tissues. The result of qPCR showed that miR-125b was upregulated in RCC tissues. Furthermore, the function of miR-125b in RCC (786-O and ACHN) cells was detected by transfecting miR-125 mimic or inhibitor to upregulate or downregulate miR-125b expression. Cell proliferation assays (MTT and Cell Counting Kit-8), cell mobility assays (cell scratch and Transwell assay) and a cell apoptotic assay (flow cytometry assay) were performed to assess the function of miR-125b on RCC cells. Results from the assays demonstrated that overexpression of miR-125b could promote cell migration and invasion, and reduce the cell apoptotic rate. It was also revealed that downregulation of miR-125b could reduce cell migration and invasion, and induce cell apoptosis. However, the results of the cell proliferation assay revealed that miR-125b had no significant effect on cell proliferation. Not only could miR-125b predict recurrence and survival of ccRCC; the present study revealed that miR-125b could regulate RCC cell migration, invasion and apoptosis. Additional studies are required to determine the mechanism of miR-125b in RCC cells and define the target genes of miR-125b in RCC.
微小RNA(miR)-125b已被证实在多种癌症类型中表达失调。以往研究通过杂交检测了透明细胞肾细胞癌(ccRCC)组织中miR-125b的表达,发现ccRCC组织中miR-125b上调,且与ccRCC患者的复发和生存相关。然而,miR-125b在肾细胞癌(RCC)中的功能仍不清楚。因此,采用定量聚合酶链反应(qPCR)检测了24对RCC组织及其相邻正常组织中miR-125b的表达。qPCR结果显示,RCC组织中miR-125b上调。此外,通过转染miR-125模拟物或抑制剂上调或下调miR-125b表达,检测了miR-125b在RCC(786-O和ACHN)细胞中的功能。进行细胞增殖实验(MTT和细胞计数试剂盒-8)、细胞迁移实验(细胞划痕和Transwell实验)以及细胞凋亡实验(流式细胞术实验)以评估miR-125b对RCC细胞的功能。实验结果表明,miR-125b过表达可促进细胞迁移和侵袭,并降低细胞凋亡率。还发现miR-125b下调可减少细胞迁移和侵袭,并诱导细胞凋亡。然而,细胞增殖实验结果显示,miR-125b对细胞增殖无显著影响。miR-125b不仅可以预测ccRCC的复发和生存;本研究还表明,miR-125b可调节RCC细胞的迁移、侵袭和凋亡。需要进一步研究以确定miR-125b在RCC细胞中的作用机制,并确定RCC中miR-125b的靶基因。